Financial results for 2006 | Innate Pharma

Tue, 03/20/2007 - 18:34

Innate Pharma SA announces its financial results for 2006: Sharp increase in R&D activities (+75%), notably in clinics.

PR in english	168.44 KB
CP en français	193.52 KB

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers